Clinical trials: HER2 Amplified
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
- Conditions
- Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma
- Trial name
- NCT05672524
- Testing
- Trastuzumab, Tucatinib
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Breast Cancer
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as…
- Trial name
- EvoPAR-BR01 (NCT06380751)
- Testing
- Saruparib (AZD5305), Camizestrant, Abemaciclib
- Where
- 306 sites in United States, Argentina and 27 more
- Volunteers
- 788 people
- Sponsor
- AstraZeneca
Breast Cancer
Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery
The goal of this clinical research study is to compare the use of an ultrasound-guided biopsy with what is found during surgery in finding evidence of the disease.
- Trial name
- NCT02455791
- Testing
- Ultrasound-Guided Biopsy
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Stomach Neoplasms, Cancer of Stomach
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
The purpose of this study is to determine whether ASLAN001 has an effect in patients with recurrent or metastatic adenocarcinoma of the stomach, gastrooesophageal junction, or lower third of the oesophagus whose tumours…
- Conditions
- Stomach Neoplasms, Cancer of Stomach, Cancer of the Stomach, Gastric Cancer
- Trial name
- NCT01614522
- Testing
- ASLAN001
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- ASLAN Pharmaceuticals
Breast Cancer
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and…
- Trial name
- NCT01111825
- Testing
- Temsirolimus, Neratinib
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 99 people
- Sponsor
- Puma Biotechnology, Inc.
HER2-positive Breast Cancer, LMD
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
The proposed study will evaluate the safety and efficacy of XRT followed by systemic therapy among patients with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer and LMD
- Trial name
- NCT06016387
- Testing
- Tucatinib 150 MG, Trastuzumab, Capecitabine
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic…
- Trial name
- NCT06413745
- Testing
- SHR-A1811
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Colorectal Cancer
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
This is a phase II trial to examine the efficacy of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (all RAS/NRAS/BRAF/PIK3CA wild-type), metastatic colorectal cancer based on HER2…
- Trial name
- NCT03457896
- Testing
- Trastuzumab, Cetuximab, Neratinib
- Where
- 48 sites in United States
- Volunteers
- 35 people
- Sponsor
- NSABP Foundation Inc
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal…
- Trial name
- NCT02650752
- Testing
- Lapatinib in Tandem With Capecitabine
- Where
- 9 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine…
- Conditions
- Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
- Trial name
- NCT07428044
- Testing
- Trastuzumab Deruxtecan
- Where
- 10 sites in United States, Canada
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Gastrointestinal Tract
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
EGF104578 is two-part study (Pilot part/Randomized part).Pilot part is designed to find the optimal (best) doses of lapatinib and paclitaxel when given together,Randomized part is designed to evaluate the overall survival in…
- Trial name
- NCT00486954
- Testing
- Lapatinib, Paclitaxel
- Where
- 17 sites in China, Japan and 2 more
- Volunteers
- 273 people
- Sponsor
- GlaxoSmithKline
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1…
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Trial name
- NCT07029399
- Testing
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Where
- 18 sites in United States
- Volunteers
- 361 people
- Sponsor
- NiKang Therapeutics, Inc.
BRMS1, Performance Status Zero to Two for Beginning the Study
Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.
Despite these initial positive signals in recent statistics, breast cancer continues to claim a substantial number of lives approximately 500,000 deaths worldwide in 2005 Thus the current treatment paradigm - surgery, radiation…
- Conditions
- BRMS1, Performance Status Zero to Two for Beginning the Study, Patient With a Maximum of One Chemotherapy, Patient With Progression After Taxanes
- Trial name
- GLICO-0801 (NCT01050322)
- Testing
- Lapatinib Vinorelbine, Lapatinib Capecitabine, Gemcitabine Lapatinib
- Where
- 18 sites in Argentina, Brazil and 1 more
- Volunteers
- 142 people
- Sponsor
- Latin American Cooperative Oncology Group
Neoplasms, Breast
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
This was a randomized, double-blind, placebo-controlled, multicenter, Phase III study to evaluate and compare the efficacy and safety of Lapatinib + Paclitaxel versus Placebo + Paclitaxel in men and women with ErbB2 amplified…
- Trial name
- NCT00281658
- Testing
- Lapatinib (GW572016) oral tablets, Paclitaxel infusion
- Where
- 54 sites in Brazil, China and 6 more
- Volunteers
- 444 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
- Trial name
- DTP (NCT03820141)
- Testing
- Durvalumab, Trastuzumab, Pertuzumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- The Methodist Hospital Research Institute
Neoplasms, Breast Neoplasms
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
- Conditions
- Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer
- Trial name
- NCT04596150
- Testing
- CX-2009, CX-072
- Where
- 42 sites in United States, South Korea and 1 more
- Volunteers
- 125 people
- Sponsor
- CytomX Therapeutics
Breast Cancer, Metastases
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
This study is a Phase IV, prospective, nonrandomized, community-based study of clinical outcomes in patients with metastatic breast cancer treated with Herceptin and a taxane.
- Trial name
- NCT00097487
- Volunteers
- 1,000 people
- Sponsor
- Genentech, Inc.
Early-stage Breast Cancer, HER2-positive Breast Cancer
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint…
- Trial name
- PREDIXIIHER2 (NCT03894007)
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- 8 sites in Sweden
- Volunteers
- 6 people
- Sponsor
- Renske Altena
HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
The investigators are doing this research program to find out if the investigational drug, afatinib which is a medication known to block the function of the ErbB2 protein might help standard chemotherapy, in particular…
- Conditions
- HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer, Esophageal Cancer
- Trial name
- NCT02274012
- Testing
- Afatinib, Paclitaxel
- Sponsor
- Columbia University
Non-small Cell Lung Cancer
Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer
This is a Phase 1, open-label study to evaluate the safety and the efficacy of inetetamab in combination with pyrotinib in patients in HER2 mutant or amplified patients with advanced non-small cell lung cancer
- Trial name
- NCT05016544
- Testing
- inetetamab, Pytotinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University